Corrigendum to: “Stereotactic Electroencephalography Is Associated With Reduced Pain and Opioid Use When Compared with Subdural Grids: A Case Series” by Jonathan P. Scoville, MD, Evan Joyce, MD, MS, Joshua Hunsaker, BS, Jared Reese, BS, Herschel Wilde, BS, Amir Arain, MD, Robert L. Bollo, MD, John D. Rolston, MD, PhD. Operative Neurosurgery, opab040, https://doi.org/10.1093/ons/opab040

Abstract BACKGROUND Minimally invasive surgery (MIS) has been shown to decrease length of hospital stay and opioid use. OBJECTIVE To identify whether surgery for epilepsy mapping via MIS stereotactically placed electroencephalography (SEEG) electrodes decreased overall opioid use when compared with craniotomy for EEG grid placement (ECoG). METHODS Patients who underwent surgery for epilepsy mapping, either SEEG or ECoG, were identified through retrospective chart review from 2015 through 2018. The hospital stay was separated into specific time periods to distinguish opioid use immediately postoperatively, throughout the rest of the stay and at discharge. The total amount of opioids consumed during each period was calculated by transforming all types of opioids into their morphine equivalents (ME). Pain scores were also collected using a modification of the Clinically Aligned Pain Assessment (CAPA) scale. The 2 surgical groups were compared using appropriate statistical tests. RESULTS The study identified 43 patients who met the inclusion criteria: 36 underwent SEEG placement and 17 underwent craniotomy grid placement. There was a statistically significant difference in median opioid consumption per hospital stay between the ECoG and the SEEG placement groups, 307.8 vs 71.5 ME, respectively (P = .0011). There was also a significant difference in CAPA scales between the 2 groups (P = .0117). CONCLUSION Opioid use is significantly lower in patients who undergo MIS epilepsy mapping via SEEG compared with those who undergo the more invasive ECoG procedure. As part of efforts to decrease the overall opioid burden, these results should be considered by patients and surgeons when deciding on surgical methods.

Download Full-text

Natural opioid use in elderly in India: a case series

Journal of Substance Use ◽

10.3109/14659891.2016.1162211 ◽

2016 ◽

Vol 22 (2) ◽

pp. 156-158 ◽

Cited By ~ 3

Author(s):

Arpit Parmar ◽

Vaibhav Patil ◽

Siddharth Sarkar

Keyword(s):

Case Series ◽

Opioid Use

Download Full-text

Perioperative Management of Buprenorphine: Solving the Conundrum

Pain Medicine ◽

10.1093/pm/pny217 ◽

2018 ◽

Vol 20 (7) ◽

pp. 1395-1408 ◽

Cited By ~ 7

Author(s):

Aurora Naa-Afoley Quaye ◽

Yi Zhang

Keyword(s):

Perioperative Management ◽

Case Reports ◽

Management Strategies ◽

Case Series ◽

Analgesic Efficacy ◽

Published Data ◽

Opioid Use ◽

Mu Opioid ◽

Periprocedural Management ◽

Opioid Agonists

Abstract Objective There is no consensus on the optimal perioperative management of patients on buprenorphine (BUP) for opioid use disorder (OUD). This article will review the available literature on BUP and the analgesic efficacy of BUP combined with full mu-opioid agonists and discuss the conflicting management strategies in the context of acute pain and our institution’s protocol for the periprocedural management of BUP. Methods We searched published data on BUP periprocedural management from inception through March 2018 without language restrictions. Study selection included publications reporting outcomes on perioperative pain management in OUD patients maintained on BUP. Results Our search resulted in four case reports supporting periprocedural discontinuation of BUP and two case series, one secondary observational study, one prospective matched cohort study, and four retrospective cohort studies supporting periprocedural continuation of BUP. No clinical trials were identified. Conclusions Maintaining BUP perioperatively does not lead to worsened clinical outcomes. Patients can receive adequate pain control from mu-opioid agonists while maintained on BUP. Based upon available evidence, we recommend continuing BUP at a reduced dose when indicated to avoid withdrawal symptoms and to facilitate the analgesic efficacy of mu-opioid agonists administered in combination for acute postoperative pain.

Download Full-text

Lofexidine for acute opioid withdrawal: A clinical case series

Mental Health Clinician ◽

10.9740/mhc.2020.09.259 ◽

2020 ◽

Vol 10 (5) ◽

pp. 259-263

Author(s):

Mandy L. Renfro ◽

Lindsey J. Loera ◽

Carlos F. Tirado ◽

Lucas G. Hill

Keyword(s):

Addiction Treatment ◽

Case Series ◽

Retrospective Chart Review ◽

The United States ◽

Opioid Withdrawal ◽

Withdrawal Symptoms ◽

Total Daily Dose ◽

Opioid Use ◽

Management Protocol ◽

Patient Reported

Abstract Introduction Maintaining abstinence through the opioid withdrawal period is a substantial barrier to treatment for patients with opioid use disorder. The alpha-2 agonist lofexidine has demonstrated efficacy and safety in clinical trials, but pragmatic studies describing its use in clinical practice are lacking. This case series describes the use of lofexidine for opioid withdrawal symptoms in an inpatient addiction treatment facility. Methods Seventeen patients receiving at least 1 dose of lofexidine during inpatient treatment for opioid withdrawal were included in this study. A retrospective chart review was conducted for clinical, subjective, and objective data. Adverse events, total daily dose, clinical opioid withdrawal scale (COWS) scores, vital signs, and reasons for early discontinuation of lofexidine are reported. Results Patients treated with lofexidine experienced mild withdrawal symptoms throughout treatment. Most patients (65%) experienced a decrease in their average daily COWS scores from intake to discharge. Two patients (12%) left treatment against medical advice, and 5 patients (29%) discontinued treatment prior to day 7 due to resolution of symptoms. Average daily blood pressure readings remained stable, and daily average heart rate decreased over time. Discussion Lofexidine can be successfully incorporated into a conventional withdrawal management protocol. The cost of lofexidine and its recent introduction to the market remain barriers to accessibility in the United States. Studies evaluating patient-reported outcomes as well as direct comparisons with other alpha-2 agonists are needed to inform optimal clinical use of lofexidine.

Download Full-text

Percutaneous Peripheral Nerve Stimulation to Control Postoperative Pain, Decrease Opioid Use, and Accelerate Functional Recovery Following Orthopedic Trauma

Military Medicine ◽

10.1093/milmed/usy378 ◽

2019 ◽

Vol 184 (Supplement_1) ◽

pp. 557-564 ◽

Cited By ~ 6

Author(s):

Brian M Ilfeld ◽

Scott T Ball ◽

Steven P Cohen ◽

Steven R Hanling ◽

Ian M Fowler ◽

...

Keyword(s):

Postoperative Pain ◽

Peripheral Nerve ◽

Nerve Stimulation ◽

Case Series ◽

Opioid Therapy ◽

Peripheral Nerve Stimulation ◽

Orthopedic Trauma ◽

Opioid Use ◽

Postamputation Pain ◽

Improved Function

Abstract Orthopedic trauma is a significant military problem, causing several of the most disabling conditions with high rates of separation from duty and erosion of military readiness. The objective of this report is to summarize the findings of case series of a non-opioid therapy—percutaneous peripheral nerve stimulation (PNS) – and describe its potential for postoperative analgesia, early opioid cessation, and improved function following orthopedic trauma. Percutaneous PNS has been evaluated for the treatment of multiple types of pain, including two case series on postoperative pain following total knee replacement (n = 10 and 8, respectively) and a case series on postamputation pain (n = 9). The orthopedic trauma induced during TKR is highly representative of multiple types of orthopedic trauma sustained by Service members and frequently produces intense, prolonged postoperative pain and extended opioid use following surgery. Collectively, the results of these three clinical studies demonstrated that percutaneous PNS can provide substantial pain relief, reduce opioid use, and improve function. These outcomes suggest that there is substantial potential for the use of percutaneous PNS following orthopedic trauma.

Download Full-text

Implementing group visits for opioid use disorder: A case series

Substance Abuse ◽

10.1080/08897077.2019.1635958 ◽

2019 ◽

Vol 41 (2) ◽

pp. 174-180 ◽

Cited By ~ 2

Author(s):

Randi Sokol ◽

Mark Albanese ◽

Chiara Albanese ◽

Gerard Coste ◽

Ellie Grossman ◽

...

Keyword(s):

Case Series ◽

Opioid Use Disorder ◽

Opioid Use ◽

Group Visits

Download Full-text

Novel treatment of opioid use disorder using ibogaine and iboga in two adults

Journal of Psychedelic Studies ◽

10.1556/2054.2020.00133 ◽

2020 ◽

Author(s):

Claire Wilson ◽

Trevor Millar ◽

Zak Matieschyn

Keyword(s):

Addiction Treatment ◽

Case Series ◽

Opioid Use Disorder ◽

Opioid Withdrawal ◽

Opioid Use ◽

Opioid Agonist ◽

Opioid Agonist Therapy ◽

Safety Risks ◽

Short Period ◽

Multiple Treatments

AbstractIbogaine is a naturally occurring psychedelic medicine with anti-addictive properties. While research on ibogaine is limited, several observational studies have shown ibogaine can mitigate opioid withdrawal, as seen with reductions in clinical and subjective opioid withdrawal scores and reduced drug use severity (Noller, Frampton, & Yazar-Klosinski, 2018; Brown & Alper 2018). Furthermore, the psychoactive experience may help individuals to realign their values, purpose and sense of connection, as seen with post treatment reductions in depression scores (Noller et al., 2018; Mash et al., 2000).Case seriesThis case series describes two cases of individuals accessing ibogaine through private unregulated clinics in the Vancouver area to treat their opioid use disorder.ConclusionsIn case 1, the client achieved total abstinence from all opioids within 5–6 days of starting ibogaine treatment, did not experience any opioid withdrawal symptoms after ibogaine treatment and maintained abstinence from opioids for 3 years. In case 2, the patient took ibogaine/iboga in multiple treatments over a short period of time (<4 months). The patient stopped all non-medical opioids after the first iboga treatment and then used ibogaine to aid with further dose reductions of her opioid agonist therapy (OAT) and has maintained abstinence from opioids for 2 years. Ibogaine offers a unique and novel therapeutic approach to treating opioid use disorder. Further studies are needed to establish the safety, risks and potential role for ibogaine as a mainstream, evidence-based addiction treatment.

Download Full-text

Case Series of Patients with Opioid Use Disorder and Suicidal Ideation Treated with Buprenorphine

Clinical Practice and Cases in Emergency Medicine ◽

10.5811/cpcem.2020.10.49610 ◽

2021 ◽

Vol 5 (1) ◽

Author(s):

Max Spaderna ◽

Melanie Bennett ◽

Rachel Arnold ◽

Eric Weintraub

Keyword(s):

Suicidal Ideation ◽

Case Series ◽

Opioid Use Disorder ◽

Opioid Use

Download Full-text

Long-Acting Injectable Antipsychotic Treatment in Schizophrenia and Co-occurring Substance Use Disorders: A Systematic Review

Frontiers in Psychiatry ◽

10.3389/fpsyt.2021.808002 ◽

2021 ◽

Vol 12 ◽

Author(s):

Alexandria S. Coles ◽

Dunja Knezevic ◽

Tony P. George ◽

Christoph U. Correll ◽

John M. Kane ◽

...

Keyword(s):

Systematic Review ◽

Substance Use ◽

Substance Use Disorders ◽

Case Series ◽

Small Sample ◽

Antipsychotic Treatment ◽

Opioid Use ◽

Open Label ◽

Effective Treatment Option ◽

Long Acting

Objectives: Co-occurring substance use disorders (SUDs) among individuals with schizophrenia are a prevalent and complex psychiatric comorbidity, which is associated with increased symptom severity, worsened illness trajectory and high rates of treatment non-adherence. Recent evidence suggests that the use of long-acting injectable (LAI) antipsychotics may provide an effective treatment option for individuals with this dual-diagnosis.Methods: A systematic review of the literature was conducted using the databases PubMed, PsychInfo and Google Scholar for English-language studies, investigating the use of LAIs in co-occurring schizophrenia and substance use disorders (SCZ-SUDs).Results: Eight reports [one case study (n = 1), one case series (n = 8), three open-label retrospective studies (n = 75), and three randomized controlled trials (n = 273)] investigated the use of LAI antipsychotics in 357 participants with SCZ-SUDs [alcohol use disorder: 5 studies, n = 282; cocaine use disorder: 5 studies, n = 85; amphetamine use disorder: 1 study, n = 1; cannabis use disorder: 3 studies, n = 160; opioid use disorder: 3 studies, n = 19; methylenedioxymethamphetamine (MDMA) use disorder: 2 studies, n = 9; ketamine use disorder: 1 study, n = 4] and were included in this systematic review. Findings indicate significant improvements in substance use related outcomes across 7 of 8 studies, while in 6 of 8 studies, significant improvements in psychopathology-related outcomes were reported.Conclusions: LAI antipsychotics may be an efficacious intervention option for the treatment of SCZ-SUDs. However, varying methodological rigor, generally small sample sizes and heterogeneity of samples, settings, substances of abuse, tested LAIs and comparators, as well as psychosocial cotreatments and level of reported detail across studies requires that these findings be considered preliminary and interpreted with caution. Further research is required to better understand the effects of LAIs among individuals with SCZ-SUDs.

Download Full-text